It is thought that CML LSCs are not completely addicted to BCR/ABL1, and several studies have shown survival of CML LSCs in the presence of Imatinib in vitro and in vivo [(28) and reviewed in Ref. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.